Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Leases for 3 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Leases fell 25.42% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, down 25.42%, while the annual FY2025 figure was $7.9 million, 25.42% down from the prior year.
  • Operating Leases hit $7.9 million in Q4 2025 for Artiva Biotherapeutics, down from $8.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $15.5 million in Q2 2024 and bottomed at $7.9 million in Q4 2025.
  • Average Operating Leases over 3 years is $10.9 million, with a median of $10.4 million recorded in 2024.
  • Year-over-year, Operating Leases decreased 20.62% in 2024 and then plummeted 38.35% in 2025.
  • Artiva Biotherapeutics' Operating Leases stood at $13.3 million in 2023, then fell by 20.62% to $10.6 million in 2024, then decreased by 25.42% to $7.9 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $7.9 million, $8.5 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.